TW200616621A - Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals - Google Patents

Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals

Info

Publication number
TW200616621A
TW200616621A TW094125600A TW94125600A TW200616621A TW 200616621 A TW200616621 A TW 200616621A TW 094125600 A TW094125600 A TW 094125600A TW 94125600 A TW94125600 A TW 94125600A TW 200616621 A TW200616621 A TW 200616621A
Authority
TW
Taiwan
Prior art keywords
alk
animals
modulate
inhibitors
lean tissue
Prior art date
Application number
TW094125600A
Other languages
English (en)
Inventor
David G Sawutz
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of TW200616621A publication Critical patent/TW200616621A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
TW094125600A 2004-07-29 2005-07-28 Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals TW200616621A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59235904P 2004-07-29 2004-07-29

Publications (1)

Publication Number Publication Date
TW200616621A true TW200616621A (en) 2006-06-01

Family

ID=35595039

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094125600A TW200616621A (en) 2004-07-29 2005-07-28 Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals

Country Status (14)

Country Link
US (1) US20060194845A1 (zh)
EP (1) EP1771171A1 (zh)
JP (1) JP2008506787A (zh)
CN (1) CN101031294A (zh)
AR (1) AR050187A1 (zh)
AU (1) AU2005280496B2 (zh)
BR (1) BRPI0513914A (zh)
CA (1) CA2576734C (zh)
MX (1) MX2007001118A (zh)
NO (1) NO20071113L (zh)
PE (1) PE20060729A1 (zh)
TW (1) TW200616621A (zh)
WO (1) WO2006025988A1 (zh)
ZA (1) ZA200700681B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
WO2008136739A1 (en) * 2007-05-04 2008-11-13 Jana Pickova Compound feed for aquaculture
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CN101684457B (zh) * 2009-07-27 2013-01-09 中国科学院广州生物医药与健康研究院 I型转化生长因子受体抑制剂在产生诱导多能干细胞中的应用及其方法
EP2694653A2 (en) * 2011-04-05 2014-02-12 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Compounds and methods for altering activin receptor-like kinase signalling
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
PT2880053T (pt) 2012-08-01 2020-05-22 Ikaika Therapeutics Llc Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4
US10265372B2 (en) 2014-08-12 2019-04-23 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2022511112A (ja) 2018-12-11 2022-01-28 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
US20220143136A1 (en) 2018-12-21 2022-05-12 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP2023502662A (ja) 2019-11-22 2023-01-25 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
US20230414711A1 (en) * 2020-11-13 2023-12-28 The Jackson Laboratory Therapeutics targeting transforming growth factor beta family signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
CN100567322C (zh) * 1999-01-21 2009-12-09 梅塔莫菲克斯公司 抑制生长分化因子活性的多肽及表达该多肽的细胞
ATE231143T1 (de) * 1999-04-09 2003-02-15 Smithkline Beecham Corp Triarylimidazole
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
JP2008506787A (ja) 2008-03-06
MX2007001118A (es) 2007-03-15
EP1771171A1 (en) 2007-04-11
WO2006025988A1 (en) 2006-03-09
BRPI0513914A (pt) 2008-05-20
US20060194845A1 (en) 2006-08-31
CN101031294A (zh) 2007-09-05
AU2005280496B2 (en) 2009-10-08
AR050187A1 (es) 2006-10-04
ZA200700681B (en) 2008-07-30
NO20071113L (no) 2007-02-27
CA2576734A1 (en) 2006-03-09
AU2005280496A1 (en) 2006-03-09
CA2576734C (en) 2010-03-16
PE20060729A1 (es) 2006-08-12

Similar Documents

Publication Publication Date Title
TW200616621A (en) Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
ATE550031T1 (de) Zusammensetzungen und verfahren für die lipomodellierung
EP2177224A3 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
TNSN08396A1 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
UA99540C2 (ru) Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
DE602007011904D1 (de) Piperazinyl-oxoalkyl-tetrahydroisochinoline und verwandte analoga
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
ATE545441T1 (de) Verfahren und vorrichtungen zur minimal invasiven abgabe von zellhaltigen fliessfähigen zusammensetzungen
CY1109031T1 (el) Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου
BRPI0916540B8 (pt) inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
ATE478661T1 (de) Verfahren zur reduzierung der angiogenese
MX2009013205A (es) Derivados de pirazoloquinolina urea terapeuticos.
MX2009013202A (es) Derivados terapeuticos de pirazoloquinolina.
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2007104933A8 (en) Chemical compounds
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
BRPI0800744A2 (pt) composiÇço de inibiÇço de infecÇço por salmonella para pinto e mÉtodo de inibiÇço de infecÇço por salmonella em pintos
BR0314821A (pt) Derivado de piperidina, composição farmacêutica, uso do derivado de piperidina, e, método para tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo animal vivo